TY - JOUR
T1 - Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer
T2 - Experience From a Single Institution
AU - Simon, George R.
AU - Ruckdeschel, John C.
AU - Williams, Charles
AU - Cantor, Alan
AU - Chiappori, Alberto
AU - Lima, Caio M.Rocha
AU - Antonia, Scott
AU - Haura, Eric
AU - Wagner, Henry
AU - Robinson, Lary
AU - Sommers, Eric
AU - Alberts, Michael
AU - Bepler, Gerold
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.
AB - Background: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. Methods: Our single-center, prospective landmark analysis included 183 patients with advanced NSCLC who received 250 mg of gefitinib orally once daily in an expanded-use program at our institution. Thirty-three of the 183 patients were previously untreated. The patients included in this analysis had all received at least 12 weeks of gefitinib. Results: The objective tumor response rate was 3.8%, but an additional 53.5% of patients experienced clinically meaningful disease stabilization. Median progression-free survival time was 3.6 months, and median overall survival time was 8.8 months. The 1-year survival rate for the entire cohort was 35%. Predictors of longer survival included female gender, adenocarcinoma or bronchoalveolar carcinoma histology, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Adverse events were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Conclusions: In this single-center experience, gefitinib demonstrated clinically significant antitumor activity and provided good palliation in a predominantly pretreated group of patients. Our results, which are likely to be reproducible in a community setting, demonstrated a 1-year survival rate of 35% in a cohort of patients who were able to take the drug for at least 12 weeks.
UR - http://www.scopus.com/inward/record.url?scp=10744229425&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744229425&partnerID=8YFLogxK
U2 - 10.1177/107327480301000506
DO - 10.1177/107327480301000506
M3 - Review article
C2 - 14581894
AN - SCOPUS:10744229425
VL - 10
SP - 388
EP - 395
JO - Cancer Control
JF - Cancer Control
SN - 1073-2748
IS - 5
ER -
